Table 3.
Weighted percentage (95% CI) of Tehranian adults meeting the definition of hypertension and recommended anti-hypertensive medication in those without anti-hypertensive medication (n = 8996) according to the 2017 ACC/AHA guideline and the 2003 JNC7 guideline based on the 5th examination (2012–2015) of TLGS data.
| Hypertension definition | Recommended anti-hypertensive medication | ||||||
|---|---|---|---|---|---|---|---|
| Weighted % | 2017 ACC/AHA guidelinea | JNC7 Guidelineb | Difference (2017 ACC/AHA –JNC7) | 2017 ACC/AHA guideline | JNC7 guideline | Difference (2017 ACC/AHA –JNC7) | |
| Overall | 89.6 | 42.7 (42.0–43.7) | 12.6 (11.9–13.3) | 30.1 (29.0–31.3) | 21.9 (21.1–22.7) | 19.3 (18.5–20.0) | 2.6 (1.4–3.8) |
| Age groups, (years) | |||||||
| 20–29 | 23.2 | 25.1 (23.1–27.0) | 4.1 (3.2–5.0) | 21.0 (18.9–23.1) | 4.5 (3.6–5.5) | 4.4 (3.5–5.3) | 0.1 (−1.0–1.0) |
| 30–39 | 28.9 | 36.7 (35.0–38.8) | 7.1 (6.0–8.2) | 29.6 (27.3–31.9) | 9.5 (8.2–10.8) | 9.2 (7.9–10.5) | 0.3 (−1.4–2.0) |
| 40–49 | 19.11 | 48.8 (46.6–50.9) | 12.9 (11.4–14.3) | 35.9 (33.3–38.4) | 21.7 (19.9–23.4) | 20.2 (18.5–22.0) | 1.5 (−0.9–4.0) |
| 50–59 | 14.3 | 57.2 (55.0–59.7) | 20.2 (18.2–22.3) | 37.0 (34.0–39.9) | 36.5 (34.0–38.9) | 32.3 (29.9–34.6) | 4.0 (1.0–7.0) |
| 60–69 | 8.5 | 59.1 (55.7–62.5) | 25.5 (22.5–28.5) | 33.6 (30.0–37.1) | 59.1 (55.7–62.5) | 44.6 (41.2–48.0) | 14.5 (1.1–18.0) |
| 70–79 | 4.09 | 63.6 (59.1–68.1) | 35.5 (31.0–40.0) | 28.1 (23.5–32.7) | 63.6 (59.1–68.1) | 55.0 (50.2–59.5) | 8.6 (4.0–13.0) |
| ≥80 | 1.9 | 61.1 (51.8–70.0) | 34.3 (25.1–43.4) | 26.8 (18.3–35.3) | 61.1 (51.9–70.2) | 57.4 (48.1–66.7) | 3.7 (−5.0–13.0) |
| Gender | |||||||
| Male | 49.8 | 50.0 (48.5–51.6) | 14.9 (13.8–16.0) | 35.1 (33.3–36.8) | 24.8 (23.6–26.0) | 21.2 (20.0–22.4) | 3.6 (1.9–5.3) |
| Female | 50.2 | 35.4 (34.0–36.7) | 10.3 (8.2–8.4) | 25.1 (23.6–26.5) | 19.1 (18.1–20.0) | 17.3 (16.4–18.2) | 1.8 (0.4–3.1) |
| 10-year risk categories | |||||||
| <5% | 84.4 | 39.0 (37.9–40.1) | 10.1 (0.9–10.7) | 28.9 (27.7–30.1) | 16.4 (15.6–17.2) | 15.1 (14.3–15.8) | 1.3 (0.2–2.3) |
| 5%-<10% | 6.5 | 59.0 (55.0–63.1) | 18.0 (14.8–21.1) | 41.0 (36.2–45.8) | 32.5 (28.7–36.3) | 29.5 (25.8–33.2) | 3.0 (−2.0–8.0) |
| 10%-<20% | 5.2 | 61.7 (57.4–66.0) | 25.6 (21.7–29.5) | 36.1 (30.9–41.3) | 61.7 (57.4–66.0) | 40.7 (36.4–45.1) | 21.0 (15.5–26.5) |
| ≥20% | 3.9 | 70.2 (66.0–74.5) | 40.9 (36.2–45.6) | 29.3 (24.5–34.1) | 70.2 (66.0–74.5) | 63.5 (59.0–68.0) | 6.7 (1.9–11.4) |
| Prevalent CVD | 5.0 | 55.0 (50.3–59.6) | 24.5 (20.4–28.5) | 30.5 (26.4–34.6) | 55.0 (50.3–59.6) | 39.1 (34.5–43.7) | 15.6 (11.3–20.0) |
Definition of Hypertension and Recommended anti-hypertensive medication based on 2017 ACC/AHA and JNC 7 were defined previously in Table 1.
2017 ACC/AHA guideline: 2017 American college of cardiology/American Heart Association guideline for the prevention, Detection, Evaluation, and Management of High Blood pressure in Adults; JNC7 guideline: seventh report of the Joint National Committee on prevention, Detection, and Treatment of High Blood pressure; CVD: Cardiovascular disease.
aUn-weighted overall percentage according to the ACC/AHA guideline:(stage 1 + stage 2) of hypertension/(Total participants not on anti-hypertensive medication) = (2712 + 1170)/8996 = 43.15%. The same approach was followed for all reported percentages.
bUn-weighted overall percentage according to the JNC7 guideline:(stage 1) of hypertension/(Total participants not on anti-hypertensive medication) = (1170)/8996 = 13%. The same approach was followed for all reported percentages.